Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 412.40M | 429.63M | 408.55M | 333.95M | 265.99M | 274.72M |
Gross Profit | 190.40M | 278.72M | 140.37M | 101.66M | 76.44M | 171.59M |
EBITDA | 61.51M | 87.80M | 87.01M | 66.13M | 50.77M | 43.92M |
Net Income | 19.94M | 31.31M | 31.26M | 18.73M | 9.97M | 9.30M |
Balance Sheet | ||||||
Total Assets | 170.10M | 450.97M | 420.86M | 403.40M | 356.29M | 287.26M |
Cash, Cash Equivalents and Short-Term Investments | 29.35M | 65.60M | 76.00M | 84.29M | 73.32M | 31.09M |
Total Debt | 19.57M | 205.26M | 166.38M | 173.20M | 180.77M | 129.42M |
Total Liabilities | 108.37M | 346.17M | 326.13M | 320.02M | 289.65M | 228.12M |
Stockholders Equity | 60.92M | 102.85M | 92.97M | 81.77M | 64.78M | 57.05M |
Cash Flow | ||||||
Free Cash Flow | 33.52M | 27.63M | 53.03M | 70.18M | 51.91M | 42.63M |
Operating Cash Flow | 47.64M | 51.13M | 63.04M | 80.69M | 57.88M | 51.26M |
Investing Cash Flow | -19.14M | -27.46M | -20.83M | -10.36M | -19.94M | -7.98M |
Financing Cash Flow | -38.52M | -34.16M | -51.23M | -60.49M | 4.88M | -26.27M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | €136.24M | 18.36 | 2.68% | 8.59% | -22.37% | ||
69 Neutral | €391.05M | 25.05 | 15.82% | 3.24% | -3.64% | -50.51% | |
65 Neutral | €20.71B | 9.37 | 7.83% | 3.51% | 0.45% | -40.36% | |
61 Neutral | €23.44M | 37.26 | ― | 6.63% | 292.55% | ||
52 Neutral | €99.39M | ― | -21.09% | 2.35% | -10.93% | -1451.56% |
Roche Bobois SA reported its 2024 annual results, showing resilience despite a challenging market environment. The company saw a slight revenue decline of 3.6% to 414 million euros, with EBITDA aligning with expectations at 74.4 million euros. The company maintained strong financial health with significant cash flows and plans to propose a dividend of 1.25 euros per share. Strategic investments in expanding owned stores in key regions like the US and China are expected to support future growth, with a positive outlook for 2025 revenue and EBITDA.